OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

  • End date
    Dec 10, 2023
  • participants needed
  • sponsor
    Wuhan Binhui Biotechnology Co., Ltd.
Updated on 4 October 2022


This Ⅱ study evaluates the safety and efficacy of intratumoral injection of OH2 in locally advanced or metastatic bladder cancer.

OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.


This is a phase Ⅱ study evaluating the efficacy and safety of OH2 in locally advanced or metastatic bladder cancer.

BH-OH2-017 is a single-arm,multicenter clinical trial. The OH2 injection will be delivered once two weeks. In the maintenance treatment period, OH2(1x10e7 CCID50/mL) will be delivered once a month.

Adverse events (AEs) are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).

Radiographic imaging studies are performed using computed tomography or magnetic resonance imaging. Measurement of cutaneous or subcutaneous lesions are conducted with calipers. Evaluation of response are performed by the investigators using both the RECIST version 1.1 and the iRECIST criteria.

Condition Advanced Bladder Carcinoma
Treatment OH2 injection
Clinical Study IdentifierNCT05248789
SponsorWuhan Binhui Biotechnology Co., Ltd.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Agree to sign informed consent, willing to follow the study procedures
Age 18 ~ 75 years old (including boundary value), male or female
ECOG 0-1
Histologically or cytologically confirmed advanced bladder cancer,relapsed and metastasized after radiotherapy or immunotherapy
Life expectancy >12 weeks
Agree to provide last surgical specimens (including paraffin blocks, paraffin embedded sections, etc.)
At least 6 weeks after previous anti-tumor treatment (radiotherapy, chemotherapy and immunotherapy) and the first administration of this trial
Appropriate organ function and hematopoietic function: neutrophil count (neut ≥ 1.5 × 109/L; White blood cell count (WBC) ≥ 3.0 × 109/L; Platelet count ≥ 100 × 109/L; Hemoglobin ≥ 90g / L; Serum creatinine ≤ 1.5 times the upper limit of normal value (ULN); AST and alt ≤ 2.5 times ULN; Serum total bilirubin ≤ 1.5 times ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 times ULN (except for patients undergoing anticoagulant therapy)
Agree to take effective contraceptive measures during treatment and at least 180 days after the last treatment

Exclusion Criteria

The primary tumor was upper urinary tract and ureteral urothelial carcinoma
Malignant tumors other than bladder urothelial carcinoma within 5 years before enrollment
①Prostate cancer with local low risk (stage ≤ T2b, Gleason score ≤ 7, PSA ≤ 20ng / ml
no recurrence after treatment (judged by reviewing PSA level))
②Low risk prostate cancer (stage T1 / T2a, Gleason score ≤ 7, and PSA ≤ 10NG / ml, in
the observed but untreated stage
③For malignant tumors that meet other inclusion criteria but have a very low risk of
metastasis or death, after standard treatment, recheck the patients whose imaging and
disease-specific tumor markers show no recurrence or metastasis, such as fully treated
cervical cancer in situ, basal or squamous cell skin cancer; Ductal carcinoma in situ
after treatment and operation
Active autoimmune diseases and need systemic treatment in the past two years (i.e
long-term use of corticosteroids or immunosuppressive drugs). Alternative therapies
(such as thyroxine, insulin or physiological corticosteroid replacement therapy for
adrenal or pituitary insufficiency) are excluded
Expected to have major surgery during the study period or had major surgery within 4
weeks before administration
Received other vaccines within 30 days before the first administration (including new
crown vaccine)
Any immune related toxicity caused by previous cancer treatment did not return to ≤
grade 1 (except for grade 2 endocrine system diseases receiving stable dose hormone
replacement therapy), and / or any other toxicity related to previous anti-cancer
treatment (except immune related toxicity) did not return to ≤ grade 2, except hair
Human immunodeficiency virus (HIV) seropositive or history of HIV infection or other
acquired immunodeficiency diseases
Long-term use of antiviral drugs, including hepatitis B (HBsAg positive and HBV DNA
equal to 2000 IU/ml at the same time, and excluding hepatitis or other causes of
hepatitis), hepatitis C (at the same time to meet the anti HCV antibody positive, and
HCV-RNA fruit is greater than the lower limit)
Uncontrolled systemic diseases, such as cardiovascular and cerebrovascular diseases
and diabetes
History of organ transplantation or stem cell transplantation
Cardiac insufficiency (patients classified as III-IV according to NY-HA of New York
Heart Association)
Lung disease (such as shortness of breath during rest or slight activity or oxygen
supplement for any reason)
Other basic diseases which would interfere with the diagnosis of the disease, or might
potentially cause serious complications
Other serious infections before administration
Alcohol addicts or history of drug abuse
History of neurological or mental disorders, such as epilepsy, dementia, poor
compliance, or peripheral nervous system disorders
Pregnancy or lactation, or expected pregnancy or childbirth during the trial period
Allergic to study drug or have a history of allergic reaction to the main and
auxiliary materials of any dosage form in the study drug
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note